Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3070 Target Snapshot

Intercellular adhesion molecule 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
200Compounds
28Assays
1Approved Drugs
217.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Intercellular adhesion molecule 1 shows clinical signal disease relevance led by multiple myeloma. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P05362. Start with multiple myeloma, then reuse UniProt P05362 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with multiple myeloma, then reuse UniProt P05362 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
multiple myeloma

Intercellular adhesion molecule 1 shows clinical signal disease relevance led by multiple myeloma. 1 linked drug remains visible in the same block.

Start review with multiple myeloma because it currently carries clinical signal support. Linked drugs include BI-505. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Intercellular adhesion molecule 1 as ChEMBL target CHEMBL3070, mapped to UniProt P05362. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Intercellular adhesion molecule 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3070
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P05362
Intercellular adhesion molecule 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Intercellular adhesion molecule 1 is the right protein anchor across sources, using UniProt P05362 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why multiple myeloma is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIntercellular adhesion molecule 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP05362
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIntercellular adhesion molecule 1
UniProt AccessionP05362
Component TypeProtein
Sequence Length532 aa

Intercellular adhesion molecule 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Intercellular adhesion molecule 1, mapped to UniProt P05362. Sequence length is 532 aa.

Mapped IDP05362
Review nameIntercellular adhesion molecule 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Intercellular adhesion molecule 1 shows clinical signal disease relevance led by multiple myeloma.

Clinical signal Phase II
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugBI-505
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with multiple myeloma because it currently carries clinical signal support. Linked drugs include BI-505. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemultiple myeloma
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

IC50216.0
EC501.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL119501 9.0 IC50 1.0 Preclinical
CHEMBL118113 8.85 IC50 1.4 Preclinical
CHEMBL117198 8.7 IC50 2.0 Preclinical
CHEMBL117279 8.7 IC50 2.0 Preclinical
CHEMBL119733 8.7 IC50 2.0 Preclinical
CHEMBL2048028 8.53 IC50 2.98 Approved
CHEMBL116070 8.52 IC50 3.0 Preclinical
CHEMBL119335 8.42 IC50 3.8 Preclinical
CHEMBL116152 8.4 IC50 4.0 Preclinical
CHEMBL117746 8.4 IC50 4.0 Preclinical
Distribution

pChEMBL Value Distribution

11
5.0
10
5.5
38
6.0
44
6.5
22
7.0
21
7.5
21
8.0
7
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

LIFITEGRAST
CHEMBL2048028
Approved 2016
Properties Compare Identifier
Assay Landscape

Assay Landscape

28
Total Assays
155
Tested Compounds
2
Assay Types
Binding — 24 assays, 155 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 15 122 7.0
single protein format 9 33 6.5
Functional — 4 assays, 14 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 4 5.6
cell-based format 2 10 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine